Skip to content

HPP JP

Human Phenotype Project Japan: Collection of deep phenotype data for the establishment of a research platform - HPP JP

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1030240731
Enrollment
2000
Registered
2025-03-13
Start date
2025-02-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none

Interventions

None listed

Sponsors

Shin Koga
Lead Sponsor
Chieko Mori
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Men and women aged 40-69 at pre-screening 2)Individuals who are capable of visiting the CTC at baseline and have a will to continue to visit the CTC throughout the follow-up period at pre-screening 3)Individuals who are able and willing to sign a consent form at the time of the baseline visit to the CTC 4)Own a smartphone and being able to use it at pre-screening

Exclusion criteria

Exclusion criteria: 1)Individuals who are pregnant or within 2 months after pregnancy 2)Individuals who are on infertility treatment or within 2 months after the last infertility treatment (women only) 3)Individuals who have malignancy, recurrent or metastatic, that is either untreated or undergoing treatment, or a certain period of time has not passed since the last treatment at pre-screening (for chemotherapy, less than 1 year from the date of the last administration; for radiotherapy, less than 2 months from the day of the last exposure) 4)Individuals who have a history of chronic or acute hepatitis 5)Individuals who have a history of HIV infection, hepatitis B or C virus infection 6)Individuals who have diagnosed with liver cirrhosis 7)Individuals who are under dialysis treatment 8)Individuals who have poorly controlled disease or symptoms (with unstable symptoms and clinical laboratory test results despite treatments) 9)Individuals who are not capable of continued participation in this study due to impaired cognitive, intellectual, or mental function

Design outcomes

Primary

MeasureTime frame
Development of medical conditions based on participant's self-reporting

Contacts

Public ContactHirayama Yumiko

Pheno.AI Japan Ltd.

yhirayama@csb.co.jp+81-354033560

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026